心血管-肾脏-代谢综合征时代的新型心血管代谢药物
本综述总结钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在心血管-肾脏-代谢综合征管理中的疗效,前者在多样患者群体中减少心血管死亡、心力衰竭住院和不良肾脏事件,且不论2型糖尿病状态;后者在减重、血糖控制及减少心血管和肾脏事件方面显示显著获益。综述还强调公平分配药物治疗的必要性及进一步精准治疗框架、政策创新和定制干预的需求。
要点
- 钠-葡萄糖共转运蛋白2抑制剂可减少心血管死亡、心力衰竭住院和不良肾脏事件,不论2型糖尿病状态。
- 胰高血糖素样肽-1受体激动剂在减重、血糖控制及减少心血管和肾脏事件方面显示显著获益。
- 需确保高风险人群公平获得药物治疗,并发展精准治疗框架和政策创新。
核心结论
- 钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在心血管-肾脏-代谢综合征管理中显示有前景的结局,包括减少心血管死亡、心力衰竭住院、不良肾脏事件、体重减轻、血糖控制改善及减少心血管和肾脏事件。
研究设计与样本
- 本综述综合了关于心脏肾脏保护药物(包括钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂)在心血管-肾脏-代谢综合征管理中疗效的近期文献。
主要发现
- 钠-葡萄糖共转运蛋白2抑制剂在多样患者群体中减少心血管死亡、心力衰竭住院和不良肾脏事件,不论2型糖尿病状态。
- 胰高血糖素样肽-1受体激动剂在体重减轻、血糖控制和减少心血管及肾脏事件方面显示显著获益。
临床怎么用
- 综述强调需要公平分配药物治疗以确保高风险人群从这些进展中获益,并需要进一步精准治疗框架、政策创新和针对心血管-肾脏-代谢综合征管理的定制干预。
- 作者讨论了通过公平视角将这些发现转化为实践以推进心血管-肾脏-代谢健康的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interplay of obesity, hypertension, hyperlipidemia, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular disease, driving elevated morbidity and mortality. CKM syndrome encompasses a continuum of interrelated metabolic, renal, and cardiovascular dysfunctions attributed to obesity, impaired glucose regulation, and chronic inflammation. This review synthesizes recent literature on the efficacy of cardiorenal protective medications including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in CKM syndrome management. Sodium-glucose cotransporter 2 inhibitor agents show promising outcomes, including reduced cardiovascular mortality, hospitalization for heart failure, and adverse kidney events across diverse patient populations, regardless of type 2 diabetes mellitus status. Similarly, glucagon-like peptide-1 receptor agonist agents demonstrate substantial benefits in weight loss, glycemic control, and reduced cardiovascular and kidney events. The review also highlights the necessity of equitable pharmacotherapy distribution to ensure that high-risk populations benefit from these advancements and the need for further precision-based therapeutic frameworks, policy innovations, and tailored interventions focused on CKM syndrome management. Finally, we discuss strategies for translating these findings into practice through an equity-focused lens to advance CKM health.
引用
- Pohlman N, Patel PN, Essien UR, et al. Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era. J Clin Endocrinol Metab. 2025. PMID: 40388382. doi:10.1210/clinem/dgaf295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。